Red Light Therapy and Autoimmune Conditions: What the Science Actually Shows

Update date: 2026.5.21 | Reading time: 11 minutes

Discussions about red light therapy and autoimmune disease tend toward extremes. Some sources sell it as a near-cure for everything from joint pain to lupus. Others dismiss it as wellness marketing. The reality is more measured, and the details matter — especially for anyone managing a serious autoimmune condition.

This guide covers what photobiomodulation (the clinical name for red light therapy) does at a cellular level, what the evidence supports for specific autoimmune conditions, and the practical considerations that should shape any decision to try it.

How Red Light Therapy Works

Red light therapy uses two main wavelength ranges — 630–660nm visible red and 810–850nm near-infrared — to influence cellular activity without generating significant heat.

The primary mechanism involves cytochrome c oxidase, a protein in the mitochondria that absorbs red and near-infrared photons. Under chronic inflammatory stress, nitric oxide accumulates and binds to this enzyme, reducing the cell's energy output. Light absorption at the right wavelengths appears to displace that inhibition, restoring ATP production and lowering oxidative stress at the same time ([Hamblin, 2017]; [de Freitas & Hamblin, 2016]).

red light autoimmune mitochondria mechanism

Red and near-infrared light is non-ionizing. Unlike UV-based phototherapy (PUVA, narrowband UVB), it does not cause direct or psoralen-mediated DNA changes in skin cells. Unlike an infrared sauna, it does not work primarily through heat. These distinctions matter for autoimmune patients, who often have legitimate reasons to avoid UV exposure.

Why It's Relevant to Autoimmune Disease

Autoimmune conditions occur when the immune system attacks the body's own tissues. By some counts there are [around 150 such conditions], with U.S. prevalence estimates ranging from roughly [3% to 9%] depending on methodology and which diseases are included. [NIH researchers have also documented a rising trend] in autoimmune biomarkers over recent decades.

While these diseases target different organs, they share pathological features: dysregulated T-cells and B-cells, overactivation of the NF-κB inflammatory pathway, and elevated cytokines such as TNF-α, IL-1β, and IL-6.

In experimental models, photobiomodulation has been shown to:

• Downregulate NF-κB activation and downstream cytokine output
• Shift macrophages from a pro-inflammatory (M1) toward an anti-inflammatory (M2) state
• Reduce oxidative stress at the mitochondrial level

These effects are reviewed in [Hamblin's 2017 paper on the anti-inflammatory mechanisms of PBM]. The biological overlap is why photobiomodulation has become a legitimate research target in autoimmune medicine — not because it is proven, but because the mechanisms are plausible enough to investigate seriously.

What the Clinical Evidence Actually Shows

The strength of evidence varies dramatically by condition.

red light autoimmune clinical use cases

Rheumatoid arthritis

This is the best-studied autoimmune application. A [2005 Cochrane review by Brosseau et al.] found that low-level laser therapy produced short-term improvements compared to placebo: pain reduced by 1.10 points on a 10-point scale, and morning stiffness reduced by roughly 27 minutes. The reviewers also noted that effects were not long-lasting and that treatment parameters varied widely across trials.

Near-infrared wavelengths penetrate deeper than visible red light, which is why most joint-focused devices combine 660nm with 810–850nm.

Psoriasis

Psoriasis has been [studied directly in red and near-infrared light trials], with documented effects on keratinocyte proliferation and local cytokine activity. [Hamblin (2017)] notes that PBM works through anti-inflammatory mechanisms distinct from UV phototherapy, which kills circulating T-cells. Among autoimmune-related skin conditions, psoriasis has some of the more credible near-term evidence.

Lupus

Photosensitivity in lupus refers specifically to UV exposure. Red and near-infrared light (630–850nm) is non-UV and does not trigger the same pathways that drive UV-induced lupus flares. That said, controlled clinical data in lupus patients is limited, and any use should be discussed with a rheumatologist first.

Multiple sclerosis

Preclinical work on near-infrared photobiomodulation for neuroinflammation is promising, and small human pilot studies have looked at fatigue and quality of life. The mechanism is biologically reasonable, but the data does not yet support claims that red light therapy treats or modifies MS.

Inflammatory bowel disease and others

Research is preliminary. Some transcutaneous protocols over the abdomen have been explored, but evidence is too thin to support clinical recommendations.

Wavelength and Tissue Penetration

Wavelength determines what tissue light can actually reach.

• 660nm (visible red) penetrates roughly 2–3mm. Useful for skin-level inflammation: psoriatic plaques, surface lesions, capillary-level circulation.
• 810–850nm (near-infrared) penetrates 5–10mm or more. Relevant for joint capsules, tendons, and deeper musculoskeletal tissue.

Devices combining both wavelengths cover surface and deeper targets in a single session, which is why dual-wavelength configurations have become standard for general autoimmune-related use.

A note on longer wavelengths: among commonly discussed photobiomodulation wavelengths, [980nm has the highest water absorption and produces the most local heating]. 1064nm produces less heating than 980nm but still involves [more thermal contribution than 810nm]. For heat-sensitive autoimmune conditions, devices focused on the well-studied 660nm and 810–850nm ranges remain the most conservative choice.

Systemic vs. Targeted Application

Most clinical studies on red light therapy for autoimmune conditions have used localized protocols — specific joints in rheumatoid arthritis, defined skin areas in psoriasis. Systemic (whole-body) protocols are far less studied.

In practice:

• Targeted devices (handheld lamps, wraps, belts) concentrate energy on a specific site at higher irradiance, which suits joint or skin-localized inflammation.
• Larger panels or mats cover broader surface area at lower irradiance per spot, which suits multi-site discomfort and general use.

Starting with the most symptomatic area and expanding coverage later, if at all, is generally a more measured approach than going whole-body first.

Safety Considerations

Red light therapy is generally well-tolerated, but a few points deserve attention for autoimmune users.

Medications. Methotrexate has been associated with photosensitivity, primarily to UV light. Hydroxychloroquine, by contrast, [is a mainstay treatment for cutaneous and systemic lupus] and is generally considered to reduce UV-related skin reactivity, not increase it. The interaction profile of disease-modifying drugs with red and near-infrared light specifically is not well-characterized, so disclose all medications to your clinician before starting.

Biphasic dose response. Photobiomodulation [follows an inverted U-curve]: too little has no effect; too much can reduce or reverse the desired response. Shorter sessions and conservative power settings are the established protocol, not overcaution.

Eye protection. Near-infrared wavelengths are invisible and do not trigger blinking. Use eye protection rated for the wavelengths your device emits.

Active flares. Most published protocols start during stable or remission phases. During a severe flare, talk to your specialist before introducing any new modality.

A Practical Starting Framework

For someone with an autoimmune condition considering red light therapy:

1. Talk to your specialist first. A rheumatologist, dermatologist, or neurologist has context that no general guide replaces.
2. Start short. 3–5 minutes per treatment site for the first two weeks.
3. Build in rest days. Every other day is enough early on. Daily use can be evaluated later.
4. Track what changes. Note session length, site, and any shifts in joint stiffness, skin, fatigue, or sleep. A simple log is more useful than impressions.
5. Don't escalate quickly. Wait 2–4 weeks before adjusting dose or duration.

Photobiomodulation is best treated as complementary to existing care, not a replacement for prescribed therapy.

What to Look For in a Device

For autoimmune users, device quality has practical safety implications, not just efficacy ones.

Credible specifications include:

• Published irradiance at stated distances (mW/cm² at 6 inches, 12 inches), not just LED count or rated wattage
• Verified wavelength peaks — 630–660nm and 810–850nm are the most studied
• Documented certifications — FDA registration or 510(k) clearance, CE marking, RoHS compliance, ISO 13485 manufacturing
• Adjustable intensity and timer settings that allow conservative starting doses

Be cautious of devices that advertise only LED count or "rated wattage." LEDs are typically driven below their rated power for thermal and longevity reasons, so rated wattage rarely reflects actual irradiance at the skin.

FAQ

Is red light therapy safe for people with lupus?
The wavelengths used (630–850nm) are non-UV and do not trigger the photosensitivity pathways involved in lupus flares. However, clinical data specifically in lupus patients is limited. Talk to your rheumatologist before starting.

Can red light therapy replace my autoimmune medications?
No. It is being studied as a complementary modality, not a substitute for disease-modifying therapy. Stopping prescribed medications without medical supervision can be dangerous.

How long until I might notice a change?
Most clinical protocols evaluate outcomes over 4–12 weeks of consistent use. Judging from the first few sessions usually isn't reliable.

What's the difference between red light therapy and UV phototherapy?
UV phototherapy (PUVA, narrowband UVB) uses ultraviolet wavelengths and works partly through effects on DNA in skin cells, often with a photosensitizing drug like psoralen. Red and near-infrared therapy uses longer, non-ionizing wavelengths and works through cellular signaling at the mitochondria. The two should not be confused.

Can I use red light therapy during a flare?
Most protocols suggest starting during stable or remission phases. During an active flare, consult your specialist first.

Do my medications interact with red light?
Methotrexate has been linked to UV photosensitivity. Hydroxychloroquine is used to protect against UV-related lupus skin reactions and is not classified as a photosensitizing drug. For red and near-infrared light specifically, the interaction profile is less established. Disclose your medication list to your clinician.

More time means better results, right?
No. Photobiomodulation has a biphasic dose response. Sessions that run too long or at too-high intensity can reduce or reverse the benefit. Start short and adjust based on response.

What wavelengths should I look for?
660nm for surface tissue and skin; 810–850nm for joints and deeper musculoskeletal targets. Dual-wavelength devices cover both.

Is full-body better than targeted use?
Most autoimmune-related clinical studies have used targeted protocols. There is no strong evidence that whole-body application outperforms targeted application for autoimmune outcomes. Starting where symptoms are loudest is reasonable.

How do I know if a device is good quality?
Look for published irradiance figures, verified wavelength peaks, and standard certifications (FDA registration or 510(k) clearance, CE, ISO 13485). Avoid devices that rely on LED count or rated wattage as their main selling point.

Key Takeaways

Red light therapy operates through documented cellular mechanisms — mitochondrial activation, reduced oxidative stress, modulation of NF-κB and downstream cytokines — that overlap with pathways involved in autoimmune disease. Clinical evidence is strongest for rheumatoid arthritis and psoriasis, preliminary but plausible for several other conditions, and not yet sufficient to position photobiomodulation as a primary autoimmune treatment.

The most useful steps for anyone with an autoimmune diagnosis are straightforward: talk to your specialist, start conservatively, use a device with documented specifications, and treat photobiomodulation as a complement to — not a substitute for — your existing care.

References

1. Hamblin, M.R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361.

2. de Freitas, L.F., & Hamblin, M.R. (2016). Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE Journal of Selected Topics in Quantum Electronics, 22(3), 7000417.

3. Brosseau, L., Welch, V., Wells, G., et al. (2005). Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews, (4): CD002049.

4. Cooper, G.S., Bynum, M.L.K., & Somers, E.C. (2009). Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. Journal of Autoimmunity, 33(3–4), 197–207.

5. National Academies of Sciences, Engineering, and Medicine (2022). Enhancing NIH Research on Autoimmune Disease. Washington, DC: National Academies Press.

6. National Institutes of Health (2020). Autoimmunity may be rising in the United States. NIH News Release.

7. Glass, G.E., et al. (2023). Photothermal effects of high-energy photobiomodulation therapies: An in vitro investigation. Photonics.

8. Anders, J.J., et al. (2022). Utilization of the 1064 nm wavelength in photobiomodulation: A systematic review and meta-analysis. Journal of Lasers in Medical Sciences.

9. Dima, A., Jurcut, C., Chasset, F., et al. (2022). Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic Advances in Musculoskeletal Disease, 14.

10. Glass, G.E. (2024). Unlocking the power of light on the skin: A comprehensive review on photobiomodulation. International Journal of Molecular Sciences.

The information in this article is for general education and is not a substitute for medical advice. If you have an autoimmune condition, consult your specialist before starting any new therapy.